Briacell Therapeutics (BCTX)

• Market cap: $25.3M
• 1 day: -0.73%
• 5 days: -1.45%
• 1 month: -62.73%
• 3 months: -58.21%
• 6 months: -43.86%
• Year to date: -43.24%
• 1 year: -89.37%
• 5 years: -99.3%
• 10 years: -99.3%
• Sector: Healthcare
• Industry: Biotechnology

About: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Employees: 4